Περίληψη:
(1) Background: Type 2 diabetes mellitus (T2DM) is the main cause of chronic kidney disease (CKD). In Greece, in a population from hospital-based diabetes clinics (n = 1759), the overall prevalence of diabetic chronic kidney disease (DCKD) was 45% including mild, moderate, and severe CKD. The aim of this study was to describe and analyze how T2DM patients with mild-to-severe CKD are managed by diabetologists in Greece and assess the achievement rates in glycemic, blood pressure and low-density lipoprotein-cholesterol (LDL-C) control. (2) Methods: This cross-sectional multicenter study took place from June 2015 to March 2016 and collected data from diabetes centers in public hospitals all over Greece. (3) Results: With regard to the anti-diabetes treatment, most participants were on metformin, DPP-4 (Dipeptidyl Peptidase-4 inhibitors) inhibitors and insulin. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers were the most prescribed medications for hypertension. For the management of dyslipidemia, most participants were on statins. For patients with DCKD, the levels of HbA1c, blood pressure and LDL-C were 7.2%, 137.7/76.9 mmHg and 95.9 mg/dL, respectively (mean values). (4) Conclusions: The outcomes of this study suggest that management of DCKD can be further improved and should be enhanced. These results may contribute to the whole health care system in Greece. In addition, the better understanding of therapeutic strategies used by diabetologists treating these patients offers educational benefits to primary care physicians, which can result in an overall more successful and efficient management of subjects with T2DM and DCKD. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Migdalis, I.N.
Papanas, N.
Ioannidis, I.M.
Sotiropoulos, A.E.
Raptis, A.E.
Dimitriadis, G.D.
Λέξεις-κλειδιά:
aldosterone antagonist; angiotensin receptor antagonist; antidiabetic agent; antihypertensive agent; antilipemic agent; atorvastatin; beta adrenergic receptor blocking agent; calcium channel blocking agent; canagliflozin; dapagliflozin; dipeptidyl carboxypeptidase inhibitor; dipeptidyl peptidase IV inhibitor; dulaglutide; empagliflozin; ezetimibe; fibric acid derivative; glucagon like peptide 1 receptor agonist; hemoglobin A1c; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; liraglutide; loop diuretic agent; low density lipoprotein cholesterol; metformin; pioglitazone; semaglutide; sodium glucose cotransporter 2 inhibitor; sulfonylurea; thiazide diuretic agent; triacylglycerol, adult; Article; blood pressure; chronic kidney failure; comorbidity; coronary artery disease; diabetes mellitus; diabetic nephropathy; diabetic patient; diabetologist; disease severity; drug choice; drug effect; dyslipidemia; female; general practitioner; glomerulus filtration rate; glycemic control; Greece; human; hypertension; hypoglycemia; kidney function; major clinical study; male; multicenter study; non insulin dependent diabetes mellitus; prevalence; randomized controlled trial (topic); renal protection
